Molecular Oncology
Volume 2, Issue 4 , Pages 349-355 , December 2008

Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer

  • Silke Lankiewicz

      Affiliations

    • AdnaGen AG, Ostpassage 7, D-30853 Langenhagen, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 72595050; fax: +49 72595040.
    • ,
  • Silke Zimmermann

      Affiliations

    • AdnaGen AG, Ostpassage 7, D-30853 Langenhagen, Germany
    • ,
  • Christiane Hollmann

      Affiliations

    • GlaxoSmithKline GmbH & Co. KG, Theresienhöhe 11, D-80339 München, Germany
    • ,
  • Tina Hillemann

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany
    • ,
  • Tim F. Greten

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany

Received 20 April 2008 ,Revised 4 September 2008 ,Accepted 4 September 2008.

References 

  1. Azuma M, Danenberg KD, Iqbal S, El-Khoueiry A, Zhang W, Yang D, et al. Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin. Colorectal Cancer. 2006;6:214–218
  2. Bralet MP, Paule B, Adam R, Guettier C. Loss of epidermal growth factor receptor expression in lymph node and liver metastases of colon carcinoma. J. Clin. Oncol. 2005;23:5844–5845
  3. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al Circulating tumor cells versus imaging – predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 2006;12:6403–6409
  4. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005;23:1803–1810
  5. Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW, et al Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer. 2006;6:125–132
  6. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 2005;23:1420–1430
  7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004;351:337–345
  8. Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, et al. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int. J. Oncol. 2005;27:317–325
  9. Elshimali YI, Grody WW. The clinical significance of circulating tumor cells in the peripheral blood. Diagn. Mol. Pathol. 2006;15:187–194
  10. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000;60:1383–1387
  11. Ge H, Gong X, Tang CK. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int. J. Cancer. 2002;98:357–361
  12. Guller U, Zajac P, Schnider A, Bosch B, Vorburger S, Zuber M, et al Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann. Surg. 2002;236:768–775
  13. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 2006;12:4218–4224
  14. Italiano A, Saint-Paul MC, Caroli-Bosc FX, Francois E, Bourgeon A, Benchimol D, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann. Oncol. 2005;16:1503–1507
  15. Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, et al Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. USA. 2006;103:7817–7822
  16. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118:277–279
  17. Koch M, Kienle P, Kastrati D, Antolovic D, Schmidt J, Herfarth C, et al. Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int. J. Cancer. 2006;118:3072–3077
  18. Lankiewicz, S., 2006. Novel tumor marker. EP1930345 [patent online]. Available from URL: http://v3.espacenet.com/origdoc?DB=EPODOC&;IDX=EP1930345&F=0&QPN=EP1930345.
  19. Lankiewicz, S., Fehm, T., 2007. Expression of epidermal growth factor receptor (EGFR) and N-terminal variants on circulating tumor cells in metastasized breast cancer patients, in: Proceedings of the 6th International Symposium on Minimal Residual Cancer. Hamburg, Germany, 70 (#036).
  20. Lankiewicz, S., Rother, E., Zimmermann, S., Hollmann, C., Korangy, F., Greten, T.F., in press. Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cell. Oncol. (in press).
  21. Meropol NJ. Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. J. Clin. Oncol. 2005;23:1791–1793
  22. Molnar B, Sipos F, Galamb O, Tulassay Z. Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. Dig. Dis. 2003;21:320–325
  23. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995;55:5536–5539
  24. Nygren P, Sorbye H, Osterlund P, Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report. Acta Oncol. 2005;44:203–217
  25. Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, Terry TR, et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br. J. Cancer. 2000;82:186–194
  26. Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene. 2007;26:3661–3678
  27. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J. Clin. Oncol. 2004;22:4720–4726
  28. Spindler KL, Olsen DA, Nielsen JN, Brandslund I, Poulsen HS, Villingshoj M, et al. Lack of the type III epidermal growth factor receptor mutation in colorectal cancer. Anticancer Res. 2006;26:4889–4893
  29. Thorban S, Rosenberg R, Maak M, Friederichs J, Gertler R, Siewert JR. Impact of disseminated tumor cells in gastrointestinal cancer. Expert Rev. Mol. Diagn. 2006;6:333–343
  30. Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, et al Molecular determinants of cetuximab efficacy. J. Clin. Oncol. 2005;23:3536–3544
  31. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, et al Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995;55:3140–3148
  32. Zhang W, Gordon M, Lenz HJ. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann. Med. 2006;38:545–551
  33. Zieglschmid V, Hollmann C, Gutierrez B, Albert W, Strothoff D, Gross E, et al. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res. 2005;25:1803–1810
  34. Zieglschmid V, Hollmann C, Mannel J, Albert W, Jaeschke-Melli S, Eckstein B, et al. Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer. Anticancer Res. 2007;27:1823–1832

PII: S1574-7891(08)00120-8

doi: 10.1016/j.molonc.2008.09.001

Molecular Oncology
Volume 2, Issue 4 , Pages 349-355 , December 2008

Article Tools

* Image Usage & Resolution